British confident of vaccine supply from manufacturers
Reuters
Published Feb 24, 2021 11:47
Updated Feb 24, 2021 13:40
By Alistair Smout
LONDON (Reuters) - Britain said on Wednesday it was confident in manufacturers' timely supply of COVID-19 vaccines to keep fuelling one of the world's fastest rollouts despite a slowdown this week.
Prime Minister Boris Johnson has accelerated the UK's vaccine rollout, aiming to give all adults a first dose by the end of July. But on Monday it recorded the lowest number of first doses given since daily figures were first reported.
"We have real confidence in our supply and our visibility of supply," vaccine deployment minister Nadhim Zahawi told lawmakers, saying the government talked to manufacturers near-daily.
"We're very confident that we can meet those targets, because we've got enough line of sight of our deliveries."
Johnson has outlined a plan to ease England's lockdown, assuming a successful vaccine rollout.
Health Minister Matt Hancock had said this week would be quieter for vaccinations due to uneven supply schedules, but he expected supplies to increase next month.
Britain is rolling out shots developed by Pfizer/BioNTech and Oxford/AstraZeneca, though Johnson has said he is concerned about the possibility of "vaccine-busting" coronavirus variants.
Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN) have said that both vaccines offer some protection again all current variants, and AstraZeneca has said it hopes the next generation of vaccine will be ready this year if needed.
"We need to be prepared if there is a need for an autumn vaccination campaign, and if that does need to be with a new version of the vaccine," Oxford vaccine developer Sarah Gilbert told lawmakers.
"Anything can happen, viruses are infinitely able to mutate, but currently I think the signs are good that we won't see a sudden escape from the vaccine with a virus that is very well able to circulate."
Britain has the fifth highest number of COVID-19 deaths globally, at over 120,000, and has reported more than 4 million cases. It has given nearly 18 million people a first dose of COVID-19 vaccine, around a third of its adult population.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.